Market capitalization | $161.24m |
Enterprise Value | $82.50m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.54 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-93.65m |
Free Cash Flow (TTM) Free Cash Flow | $-72.76m |
Cash position | $79.70m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Immunic, Inc. forecast:
6 Analysts have issued a Immunic, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -94 -94 |
22%
22%
|
|
Depreciation and Amortization | 0.11 0.11 |
38%
38%
|
|
Stock Compensation | 7.10 7.10 |
10%
10%
|
|
Operating Cash Flow | -71 -71 |
9%
9%
|
|
Investments | 0.33 0.33 |
200%
200%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -71 -71 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Head office | United States |
CEO | Daniel Vitt |
Employees | 77 |
Founded | 2003 |
Website | imux.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.